Transaction
Mallinckrodt Agrees to Sell BioVectra Inc. to H.I.G. Capital for $250 Million
BIOVECTRA
PR-M09-19-NI-037Sep 13, 2019
M&A
Mallinckrodt and Silence Therapeutics Announce Collaboration to Develop And Commercialize RNAi Therapeutics for Complement-Mediated Diseases
Mallinckrodt Pharmaceuticals
PR-M07-19-NI-059Jul 23, 2019
Generics
Mallinckrodt Modifies Specialty Generics Spinout Portfolio Composition
Nice Insight
PAO-M06-19-NI-004Jun 13, 2019
Generics
Mallinckrodt Updates Plans for Company Separation and Spin-Off of Specialty Generics Business to Shareholders
Mallinckrodt Pharmaceuticals
PR-M05-19-NI-087May 31, 2019
Research
Mallinckrodt Presents Data on Cutaneous T-cell Lymphoma at 2019 American Academy of Dermatology Annual Meeting
Mallinckrodt Pharmaceuticals
PR-M03-19-NI-013Mar 06, 2019
Spin-off Business
Mallinckrodt Spins off its Generics Business
Pharma's Almanac
PAO-M12-18-NI-005-11Dec 11, 2018
Rheumatology
Mallinckrodt Presents Data on H.P. Acthar® Gel (Repository Corticotropin Injection) in Rheumatoid Arthritis (RA) at the 2018 ACR/ARHP Annual Meeting
Mallinckrodt Pharmaceuticals
PR-M10-18-NI-092Oct 26, 2018
Skin Graft
Mallinckrodt's Stratatech Company Awarded $26 Million in Additional BARDA Funding for Pediatric Studies of StrataGraft® Skin Tissue in Thermal Burns
Mallinckrodt Pharmaceuticals
PR-M10-18-NI-063Oct 18, 2018
Licensing Agreement
Cancer Prevention Pharmaceuticals Completes North American Licensing Deal with Mallinckrodt
Cancer Prevention Pharmaceuticals
PR-M09-18-NI-008Sep 05, 2018
Collaborative Research Partnership
Mallinckrodt Forms Collaborative Research Partnership with Washington University in St. Louis
Mallinckrodt Pharmaceuticals
PR-M08-18-NI-056Aug 14, 2018
Clinical Data
Mallinckrodt Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar® Gel (Repository Corticotropin Injection) Achieves its Enrollment Target
Mallinckrodt Pharmaceuticals
PR-M07-18-NI-009Jul 03, 2018
Scientific Advisory Council
Mallinckrodt Launches Scientific Advisory Council
Mallinckrodt Pharmaceuticals
PR-M06-18-NI-081Jun 25, 2018
FDA Acceptance
Mallinckrodt Receives FDA Acceptance of Stannsoporfin New Drug Application Filing
Mallinckrodt Pharmaceuticals
PR-M02-18-NI-106Feb 28, 2018
Clinical Trials
Mallinckrodt Enrolls First Patient in Phase 1 Study of ExpressGraft™C9T1 Skin Tissue
Mallinckrodt Pharmaceuticals
PR-M02-18-NI-74Feb 20, 2018
Acquisition
Mallinckrodt Completes Acquisition Of Sucampo Pharmaceuticals, Inc.
Mallinckrodt Pharmaceuticals
PR-M02-18-NI-62Feb 16, 2018
Acquistion
Mallinckrodt Expands Rare Disease Pipeline with Sucampo Acquisition
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M01-18-NI-017Jan 11, 2018
Acquisition
Mallinckrodt Expands Pipeline with Ocera Therapeutics Buy
Nice Insight
PAO-M11-17-NI-020Nov 10, 2017
Acquisition
Mallinckrodt Acquires InfaCare Pharmaceutical Corporation for $425 Million
Nice Insight
PAO-M08-17-NI-023Aug 17, 2017